We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > BLINCYTO

News List

Amgen’s Blincyto gets US approval for acute lymphoblastic leukaemia pharmaceutical-technology
April 09, 2018
Amgen has received approval from the US Food and Drug Administration (FDA) for Blincyto, a drug to treat B-cell precursor acute lymphoblastic leukaemia (ALL) in adults and children.
FDA expands approval of Blincyto for treatment of a type of leukemia in patients who have a certain risk factor for relapse biospace
March 30, 2018
FDA granted accelerated approval to Blincyto (blinatumomab) to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD)
Amgen’s Blincyto wins full US approval Pharmatimes
July 17, 2017
Amgen’s Blincyto has been issued a full approval in the US as a treatment for adults and children with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).

Previous page 1 2 Next page